The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Prof. Marek Trneny | EBMT 2018 | What were the most interesting results from EBMT?

Mar 23, 2018

Prof. Marek Trneny discusses key results from the 44th Annual Meeting of the European Society for Blood and Marrow Transplantationfrom the following abstracts:

- Abstract OS1-3: Monica Baile on behalf of GELTAMO: Lenalidomide together with R-ESHAP shows significant activity in relapsed/refractory DLBCL (ORR 65% and CR 37%), to note: on third of pts were not R/R but PRs only after the induction
- Abstract OS1-7: Enrico Derenzini on behalf of Italian centers: Pretransplant  immune checkpoint activation (PD1/PDL1 and LAG3) is connected with worse outcome after alloSCT
- Abstract OS1-6: Leopold Sellner on behalf of LWP EBMT: Idelalisib treatment for follicular lymphoma as bridging before alloSCT is feasible, with 70% PFS and 71% OS at 12 months
- Abstract WP7-6: Anne-Claire Mamez on behalf of French-speaking Europe: Promising results of AlloSCT in T-cell lymphomas, n 284, 2years OS and PFS were 68% and 64% resp

What were the most interesting results from EBMT?